Moderna (MRNA) announced earlier today that the FDA has approved the supplemental biologics license application for Spikevax, the company’s COVID-19 vaccine, in children 6 months through 11 years of age who are at increased risk for COVID-19 disease. Moderna expects to have its updated Spikevax vaccine available for eligible populations in the U.S. for the 2025-2026 respiratory virus season.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA: